# Bijoy Hans (NSE: BIJHANS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/BIJHANS · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹292 Cr, it ranks 2066th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Distribution.

Its return on equity was 3.9% in FY25.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹292 Cr |
| ROE | 3.9% (FY25) |
| ROCE | −10.2% (FY25) |
| Debt to equity | 0 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹0 Cr | ₹0 Cr |
| FY24 | ₹0 Cr | −₹0 Cr |
| FY23 | ₹0 Cr | −₹0 Cr |
| FY22 | ₹0 Cr | −₹0 Cr |
| FY21 | ₹0 Cr | −₹0 Cr |
| FY20 | ₹0 Cr | −₹0 Cr |

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Aarey Drugs & Pharmaceuticals](https://app.pivotnow.in/stock/AAREYDRUGS) | ₹111.75 | ₹317 Cr | 80.4 | — |
| [Lyka Labs](https://app.pivotnow.in/stock/LYKALABS) | ₹82.64 | ₹299 Cr | — | — |
| [Astonea Labs](https://app.pivotnow.in/stock/ASTONEALAB) | — | ₹281 Cr | — | — |
| [Ambalal Sarabhai Enterprises](https://app.pivotnow.in/stock/AMBALALSA) | ₹36.20 | ₹277 Cr | 15.6 | — |
| [Espire Hospital](https://app.pivotnow.in/stock/ESPIRE) | — | ₹274 Cr | — | — |
| [Zenotech Labs](https://app.pivotnow.in/stock/ZENOTECH) | — | ₹270 Cr | — | — |

## Questions and answers

### What is the market cap of Bijoy Hans?

Bijoy Hans' market capitalisation is ₹292 Cr (₹292 Cr) at the 22 Oct 2026 close, ranking 2066th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Bijoy Hans?

Return on equity was 3.9% in FY25 and return on capital employed was −10.2% in FY25 (standalone figures).

### Is Bijoy Hans a debt-free company?

Bijoy Hans is close to debt-free: its debt-to-equity ratio was 0 in FY25.

### Who are Bijoy Hans' competitors?

The listed Pharma & Healthcare companies closest to Bijoy Hans by market cap are Aarey Drugs & Pharmaceuticals, Lyka Labs, Astonea Labs, Ambalal Sarabhai Enterprises, Espire Hospital and Zenotech Labs.

### Is Bijoy Hans a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Bijoy Hans' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BIJHANS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.